IR-Med Inc. IRME
Set alert
At close · Oct 30
- YTD
- -93.00%
- 1 year
- -93.81%
- Open
- 0.0499
- Prev close
- 0.0021
- Mkt cap
- 231.13K
- Vol
- 594
- Avg vol
- 0
- EPS
- -0.04
- P/E
- 0.00
More statistics
- Low
- 0.0499
- High
- 0.0499
- Earnings
- Aug 13, 2024
News
1 month ago globenewswire.com
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
ROSH PINNA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- IR-MED Ltd. (OTC: IRME) (the "Company" or "IR-Med"), developer of infrared spectroscopy-based medical device technology,, and Dice Technologies…
12 months ago newsfilecorp.com
IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
DiaSafe™ technology for non-invasive DFU risk assessment and early intervention* The DFU treatment market is estimated to be approximately$10 billion globally 1 Rosh Pina, Israel--(Newsfile Corp. -…
1 year ago newsfilecorp.com
IR-MED's Key Clinical and Media Milestones
PressureSafe(TM) clinical results presented to global nursing leaders; the Company engages with U.S. investment community and national media in parallel visibility push Rosh Pina, Israel--(Newsfile…
1 year ago newsfilecorp.com
IR-MED Investor Update Letter - Sept-2025
Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial intelligence (AI)-powered spectrographic…
1 year ago newsfilecorp.com
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdown Technology addresses longstanding disparities in…
1 year ago newsfilecorp.com
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers for assessment of diabetic foot ulcers The most common cause of amputation, diabetic…
1 year ago globenewswire.com
IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
Rosh Pina, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- IR-MED Inc. (“IR-MED” or the “Company”) (OTCQB: IRME), a developer of noninvasive, AI-driven spectrographic analysis technology addressing…
2 years ago globenewswire.com
Methodist Healthcare Adopts IR-MED's PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
Rosh Pina, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis…
2 years ago globenewswire.com
IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
Rosh Pina, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis…
2 years ago globenewswire.com
IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company
Rosh Pina, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis…
2 years ago globenewswire.com
IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
Rosh Pina, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- I R-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis…
2 years ago globenewswire.com
IR-MED's PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel's Largest HMO
Poster presentation available here: LINK
2 years ago globenewswire.com
IR-MED's PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
Rosh Pina, Israel, April 05, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis…
2 years ago globenewswire.com
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
Rosh Pina, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis…
2 years ago globenewswire.com
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
Rosh Pina, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis…
2 years ago globenewswire.com
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
The Granted patent covers IR-MED's PressureSafe ™ decision support device for the early detection of pressure injuries addressing a healthcare burden that amounts to $26.8 billion in the U.S.…
3 years ago globenewswire.com
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
Mr. Di-Cori's vast healthcare experience includes President of LifeWatch Technologies, a developer of technologies that help physicians detect symptoms before they become major health problems
3 years ago globenewswire.com
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
Rosh Pina, Israel, Sept. 26, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis…
3 years ago globenewswire.com
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
Rosh Pina, Israel, Sept. 13, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), a developer of a noninvasive AI-driven spectrographic analysis technology platform to…
3 years ago globenewswire.com
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
Rosh Pina, Israel, Aug. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven infrared spectrographic analysis technology platform…